Erasca (NASDAQ:ERAS) Stock Jumps 5.4% – What’s Next?

Erasca, Inc. (NASDAQ:ERAS – Get Free Report)’s share price traded up 5.4% during trading on Thursday. The company traded as high as $14.54 and last traded at $14.5070. Approximately 2,064,523 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 5,839,608 shares. The stock had previously closed at $13.76.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Guggenheim increased their target price on shares of Erasca from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. HC Wainwright upped their price target on shares of Erasca from $18.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Leerink Partners started coverage on shares of Erasca in a research note on Tuesday. They issued an “outperform” rating and a $35.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Erasca in a research report on Tuesday, September 8th. Finally, Bank of America upped their target price on Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Nine equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Erasca has a consensus rating of “Moderate Buy” and a consensus target price of $23.17.

View Our Latest Research Report on Erasca

Erasca Stock Up 3.6%

The company has a market capitalization of $5.00 billion, a PE ratio of -14.33 and a beta of 0.68. The business has a 50 day simple moving average of $14.85 and a 200 day simple moving average of $15.32.

Erasca (NASDAQ:ERAS – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Equities analysts expect that Erasca, Inc. will post -0.51 EPS for the current fiscal year.

Institutional Trading of Erasca

Several institutional investors have recently modified their holdings of ERAS. Wealthcare Advisory Partners LLC grew its position in Erasca by 5.0% in the 2nd quarter. Wealthcare Advisory Partners LLC now owns 15,924 shares of the company’s stock valued at $292,000 after buying an additional 756 shares during the last quarter. Nykredit A S acquired a new stake in shares of Erasca in the 2nd quarter worth $29,000. Allworth Financial LP purchased a new stake in shares of Erasca in the second quarter valued at about $34,000. EverSource Wealth Advisors LLC increased its stake in shares of Erasca by 77.8% during the first quarter. EverSource Wealth Advisors LLC now owns 4,249 shares of the company’s stock worth $69,000 after acquiring an additional 1,859 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in Erasca by 9.3% in the 3rd quarter. ProShare Advisors LLC now owns 39,799 shares of the company’s stock valued at $583,000 after purchasing an additional 3,391 shares in the last quarter. Institutional investors and hedge funds own 67.78% of the company’s stock.

Erasca Company Profile

(Get Free Report)

Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.

Featured Articles

Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.